Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | MC4R | P32245 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | PHGDH | O43175 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28127159 | 0.89 | SIGMAR1 (0.41) | SIGMAR1MC4RMEN1KMT2ATSHR | |
| SCHEMBL7570843 | 0.84 | SIGMAR1 (0.53) | SIGMAR1MC4RMEN1KMT2ATSHR | |
| SCHEMBL5190470 | 0.84 | GAA (0.47) | SIGMAR1MC4RMEN1KMT2ATSHR | |
| SCHEMBL17459862 | 0.81 | KMT2A (0.43) | MEN1KMT2ATSHRGAALMNA | |
| SCHEMBL25000121 | 0.78 | CYP2D6 (0.43) | SIGMAR1MEN1KMT2ATSHRGAA | |
| SCHEMBL31105377 | 0.78 | CYP2D6 (0.43) | SIGMAR1MEN1KMT2ATSHRGAA | |
| SCHEMBL27314788 | 0.78 | SIGMAR1 (0.53) | SIGMAR1MC4RMEN1KMT2ATSHR | |
| SCHEMBL29528022 | 0.75 | SIGMAR1 (0.53) | SIGMAR1MC4RMEN1KMT2AGAA | |
| SCHEMBL16684766 | 0.75 | OPRL1 (0.51) | SIGMAR1MEN1KMT2ATSHRGAA | |
| SCHEMBL6133227 | 0.75 | ALDH1A1 (0.39) | SIGMAR1MC4RMEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776859-B2 | Hexahydroimidazopyrazin-3-one compounds useful as modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776859-B2 | Hexahydroimidazopyrazin-3-one compounds useful as modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776859-B2 | Hexahydroimidazopyrazin-3-one compounds useful as modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-17 | — | — | US | disclosed |
| US-20070088039-A1 | Hexahydroimidazopyrazin-3-one compounds useful as modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-19 | — | — | US | disclosed |
| US-20070088039-A1 | Hexahydroimidazopyrazin-3-one compounds useful as modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-19 | — | — | US | disclosed |
| US-20070088039-A1 | Hexahydroimidazopyrazin-3-one compounds useful as modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088039-A1 | Hexahydroimidazopyrazin-3-one compounds useful as modulators of androgen receptor function | AR, FSHR, NR5A1 | SIGMAR1 168/4885MC4R 237/4885MEN1 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.